Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]
Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
LOS ANGELES, July 27, 2017 — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that it has received official minutes of the meeting held recently between the U.S. Food and Drug Administration (FDA) and Capricor to discuss the development of intravenous CAP-1002 (allogeneic cardiosphere-derived cells) for the treatment of Duchenne muscular dystrophy (DMD).
2017 Stem Cell Industry Metrics [Infographic]
Over the few decades, potential applications for stem cells have expanded to include their use as:
- Research tools
- Cell therapies
- Source materials for 3D printing and 3D weaving
- Drug target validation
- Toxicology screening
- And More
PLX-R18 Supports Hematological Recovery After Low Radiation Exposure
-
Findings pave the way to potentially use PLX-R18 to support hematological recovery following radiotherapy or chemotherapy
-
Data focuses on 12 additional NHPs that were exposed to lower radiation levels
HAIFA, ISRAEL, JULY 26, 2017— Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, today presented new data at the RITN (Radiation Injury Treatment Network) conference from a recent study evaluating PLX-R18 as a treatment for Acute Radiation Syndrome (ARS). [Read more…]
Dr. Vincent Burton Named President of Okyanos Center for Regenerative Medicine
Changes in Ownership and Management Structure of Grand Bahama-Based Adult Stem Cell and Regenerative Medicine Center Signal Expansion and Growth
FREEPORT, GRAND BAHAMA, JULY 26, 2017 — Vincent R. Burton, MBBS, FRCA, has been appointed President of Okyanos Center for Regenerative Medicine, which is licensed by the Bahamas’ National Stem Cell Ethics Committee (NSCEC).
Dr. Burton received his Bachelor of Medicine, Bachelor of Surgery degree (MBBS) from the University of the West Indies. He went on to complete residency training in the United Kingdom at Queen’s Hospital of Staffordshire, Norfolk and Norwich University Hospital as well as Cambridge University’s Addenbrooke’s Hospital. He is a Fellow of the Royal College of Anaesthetists (FRCA) and has served as Chief Anesthesiologist at Okyanos since the center opened in 2014. [Read more…]
- « Previous Page
- 1
- …
- 258
- 259
- 260
- 261
- 262
- …
- 334
- Next Page »